ARCHIVES

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

DCE Board Approves Recompetition Of Large Support Contracts

March 16, 1990

Swiss Report On Radiotherapy Mortality Questioned

January 7, 1977

NCAB Gives Life To Three CBCCP Contractors Marked For Termination; Compromise “Reasonable” – DeVita

May 30, 1980

Prostatectomy Lowers Death Risk Compared to Watchful Waiting

April 29, 2011

Steven Curley Named Chief of Surgical Oncology At Baylor’s Dan L. Duncan Cancer Center

October 4, 2013

Xeloda, Taxotere, Herceptin Combination May Benefit Invasive Breast Cancer

January 25, 2008